INTRODUCTION {#s1}
============

Racial and ethnic disparities in the incidence, stage at diagnosis, treatment, and survival of patients with lung cancer have been described; however, the reasons for these disparities are not completely understood.^[@B1]^ It is estimated that the ethnic and racial composition of the United States will change dramatically in the next few decades.^[@B2]^ Given this, it is paramount that racial and ethnic health care disparities be studied and steps taken to have a positive impact on health outcomes. To effectively target and eliminate lung cancer--related health care disparities, a better understanding of the molecular characteristics of the disease and their relationship with race and ethnicity is needed.

Activating mutations in the epidermal growth factor receptor (*EGFR*) gene confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced non--small-cell lung cancer (NSCLC).^[@B3]-[@B6]^ Racial, ethnic, and demographic differences in the distribution of such mutations have been previously described. For example, activating *EGFR* mutations are significantly more common in East Asians, women, and never-smokers.^[@B7]^ The frequency of *EGFR* mutations varies from approximately 10% of lung adenocarcinomas in North America and Europe to as high as 50% to 60% in Asia.^[@B8],[@B9]^ However, there are limited and conflicting reports of the frequency of *EGFR* mutations among Latinos (also referred to as Hispanics). Published reports have been limited to retrospective cohorts that are constrained, among other factors, by patient selection for mutation testing based on clinical characteristics.^[@B10],[@B11]^

According to the US Census Bureau, Latinos currently comprise 17.4% of the US population and are projected to grow to 29% of the population by 2060---more than one quarter of the total population.^[@B2]^ Lung cancer is the third most commonly diagnosed cancer among Latino men and women; it is the leading cause of cancer death among Latino men and the second-leading cause among Latino women.^[@B12]^ The incidence, clinical course, and outcomes of lung cancer among Latinos are distinct from non-Latino whites, who currently constitute the largest racial and ethnic group in the United States. Lung cancer incidence rates are lower among Latinos^[@B13]^; however, despite the lower socioeconomic status, more limited access to care, and diagnoses at advanced stages of disease that would predict otherwise, lung cancer mortality rates are 50% lower among Latinos than non-Latino whites.^[@B13],[@B14]^ Although this so-called Latino paradox is still a matter of debate, given the limited reports to date,^[@B10],[@B11]^ there is a clear need for a more comprehensive molecular characterization of NSCLC in this ethnic group to better understand outcome disparities in the United States. In particular, patients with *EGFR* mutations are known to have better survival than patients with wild-type *EGFR*.^[@B15]^

In this prospective study, using central testing, we sought to characterize the types and frequencies of *EGFR*-activating mutations among Latino patients with NSCLC living in the United States and Latin America and compare them with US non-Latinos.

PATIENTS AND METHODS {#s2}
====================

Participants {#s3}
------------

This study was conducted at the following institutions: National Cancer Institute (NCI; Bethesda, MD; coordinating center), Oregon Health and Science University (OHSU; Portland, OR), Instituto Nacional de Enfermedades Neoplasicas (Lima, Peru), Instituto Nacional de Cancerologia (Mexico City, Mexico), Hospital Oncologico Luis Razetti (Caracas, Venezuela), Denver Health Medical Center (Denver, CO), and Universidad Mayor de San Simon (Cochabamba, Bolivia).

Samples from patients with histologically confirmed NSCLC were collected from two protocols that were registered with clinicaltrials.gov: NCT01306045 (CUSTOM; Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies Trial) and NCT01255150 (Frequency of EGFR Mutations in Latinos With Non-Small Cell Lung Cancer). Patients eligible for NCT01306045 had histologically confirmed advanced NSCLC for whom surgical resection or multimodality therapy with curative intent was not feasible. Patients had to have biopsiable disease and be willing to undergo biopsy for molecular profiling or had to have enough and adequate archival material from a previous biopsy to perform molecular profiling analyses. For protocol NCT01255150, all samples were collected from patients with histologically confirmed NSCLC who were dead at the time of tissue collection. For the purposes of both studies, the terms Hispanic or Latino included individuals who self-identified as Hispanic or Latino or were born in any Latin American country.

*EGFR* mutation testing was performed centrally at Clinical Laboratory Improvement Amendments (CLIA) --certified central laboratories of the NCI or OHSU. *EGFR* mutation analysis of exons 18 through 21 was performed with either pyrosequencing at the NCI or Sequenom MassArray (San Diego, CA) at OHSU. The institutional review boards of the participating centers approved the research protocol, and all living participants provided written informed consent. Tumor samples from dead individuals for whom basic clinical information was available were included in this analysis.

Pyrosequencing {#s4}
--------------

DNA was extracted from paraffin-embedded tissue sections using the Qiagen QIAamp DNA FFPE Tissue Kit (Hilden, Germany), according to manufacturer's instructions. For identification of point mutations, coamplifications at lower denaturation temperature--polymerase chain reaction (PCR; cold PCR) were performed either individually or in a single 96-well microtiter plate (complete gene panel) in an Applied Biosystems (ABI) 9700 thermocycler (Foster City, CA). After PCR, the products were subjected to pyrosequencing on a Qiagen PyroMark Q24 system. For identification of deletions and insertions, independent PCR reactions were performed with fluorescein-labeled primers in the ABI 9700, and the products were analyzed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer. Five PCR reactions were designed to interrogate the most commonly occurring mutations, including deletion mutations in exon 19, point mutations (codons 858, 861, and 863) in exon 21, insertions and point mutations in exon 20 (codon 790), and mutations at codon 719 in exon 18. The products of the exon 20, exon 21, and exon 18 reactions were analyzed by pyrosequencing, and the products of deletion mutations in exon 19 and insertions in exon 20 were analyzed by capillary electrophoresis, as described.^[@B16]^

Sequenom MassArray {#s5}
------------------

Initial PCR reactions were set up with an EpMotion 5075 liquid handler (Eppendorf, Hamburg, Germany) and used 10-ng DNA per multiplex in a total volume of 5 μl, with 100 nmol/L of primers, 2 mmol/L of magnesium chloride, 500 μmol/L of deoxynucleotide, and 0.1 units of Taq polymerase. Amplification included one cycle at 94°C for 4 minutes, followed by 45 cycles at 94°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute and one final cycle at 72°C for 3 minutes. Unincorporated nucleotides were inactivated by addition of 0.3 units of shrimp alkaline phosphatase and incubation at 37°C for 40 minutes, followed by heat inactivation of shrimp alkaline phosphatase at 85°C for 5 minutes. Single-base primer extension reactions were performed with 0.625 to 1.25 μmol/L of extension primer and 1.35 units of TypePLEX thermosequenase DNA polymerase (Sequenom). Extension cycling included one cycle at 94°C for 30 seconds, and 40 cycles at 94°C for 5 seconds, five cycles at 52°C for 5 seconds and 80°C for 5 seconds, followed by one cycle at 72°C for 3 minutes. Extension products were purified by incubation for 30 minutes with an ion exchange resin (SpectroCLEAN; Sequenom), and approximately 10 nl of purified product was spotted onto SpectroChip II matrices (Sequenom). A Bruker matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MassARRAY Compact; Sequenom) was used to resolve extension products. MassARRAY Typer Analyzer software (Sequenom) was used for automated data analysis, accompanied by visual inspection of extension products.

Statistical Analyses {#s6}
--------------------

Analyses were performed using Fisher's exact test or Mehta's modification to Fisher's exact test to determine relationships among parameters, whether for all patients or by adenocarcinoma or not, smoking or not, and center and country effects. All *P* values are two tailed and reported without adjustment for multiple comparisons.

RESULTS {#s7}
=======

Demographic Characteristics {#s8}
---------------------------

We collected samples from 642 patients with NSCLC from seven institutions in the United States and Latin America. *EGFR* mutation analysis was successfully performed in 480 (75%) of 642. Among patients who had a successful mutation analysis, 90 (19%) were Latinos, 318 (66%) were non-Latino whites, 35 (7%) were non-Latino Asians, 30 (6%) were non-Latino blacks, and seven (2%) were of other races or ethnicities. Women accounted for 53% (255 of 480) of patients and men for 46% (220 of 480). Most patients were either age 40 to 64 years (259 \[54%\] of 480) or age 65 years or older (203 \[42%\] of 480; [Table 1](#T1){ref-type="table"}). Adenocarcinoma was the most frequent histology (370 \[77%\] of 480), and never-smokers accounted for 34% (165 of 480) of patients. The majority of patients were from the United States (420 \[88%\] of 480), whereas patients from Peru, Bolivia, Venezuela, and Mexico accounted for 6%, 3%, 2%, and 2%, respectively. Most of the patients who enrolled were current or former smokers (306 \[64%\] of 480) and had advanced disease (stage IIIb to IV; 447 \[93%\] of 480).

###### 

Patient Demographic and Clinical Characteristics
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Among Latinos who had a successful *EGFR* mutation analysis, those from the United States (30 \[33%\] of 90) and Peru (27 \[30%\] of 90) accounted for the majority. In this population, 42% (38 of 90) were age older than 65 years, 54% (49 of 90) were women, 73% (66 of 90) had adenocarcinoma histology, 47% (42 of 90) were current or former smokers, and 63% (57 of 90) had advanced disease.

*EGFR* Mutations in Latinos {#s9}
---------------------------

*EGFR* mutations were detected in 22% (105 of 480) of patients overall ([Table 2](#T2){ref-type="table"}). Among Latinos, *EGFR* mutations were found in 23.3% (21 of 90), and the frequency varied based on the country of origin. The highest frequency was observed in Latinos from Peru (37%) followed by the United States (23%), Mexico (18%), Venezuela (10%), and Bolivia (8%). Among non-Latinos, the overall frequency of *EGFR* mutations was 21.5% (84 of 390), and the frequency varied based on race. The highest frequency was observed in Asians (57.1%) followed by whites (18.6%) and blacks (10%; 95% CI, 2.11 to 26.53).

###### 

*EGFR* Mutation Frequency
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*EGFR* exon 19 deletions were the most frequent type of mutation among Latinos (10 \[47.6%\] of 21; [Table 3](#T3){ref-type="table"}) followed by *EGFR* L858R and exon 20 insertions, which were found in 38% (eight of 21) and 9.5% (two of 21) of patients, respectively. *EGFR* exon 19 deletions were also the most frequent subtype of mutations among whites, Asians, and blacks, with frequencies ranging from 10% (three of 30) in blacks to 57% (20 of 35) in Asians. The frequency of *EGFR* L858R mutations was 25% each in Asians (five of 20) and whites (15 of 59); additionally, one (5%) of 20 Asians and seven (11.8%) of 59 whites had concurrent *EGFR* L858R and T790M mutations.

###### 

*EGFR* Mutation Subtypes
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*EGFR* Mutation Frequency Among Racial or Ethnic Subgroups {#s10}
----------------------------------------------------------

There was a significant difference in the frequency of *EGFR* mutations among the different racial and ethnic subgroups analyzed in the study (*P* \< .05), which was primarily driven by the high frequency of *EGFR* mutations seen in non-Latino Asians and the low frequency observed in non-Latino blacks. However, there was no significant difference in *EGFR* mutation frequency overall between Latinos (23%) and non-Latinos (22%; *P* = .78; [Table 4](#T4){ref-type="table"}). In addition, there was no significant difference in the frequency of *EGFR* mutations between Latinos and non-Latino whites (overall, 21 of 90 *v* 59 of 318; *P* = .37 *v* .54 accounting for location) and between patients enrolled in the United States and those enrolled in Latin America (non-US patients; *P* = .74). Although the *EGFR* mutation frequency seemed to be higher in patients from Peru compared with patients of other races or ethnicities, this difference only exhibited a trend toward being statistically significant (*P* = .058), and the association was further diminished greatly when smoking and adenocarcinoma histology subgroups were analyzed independently (data not shown).

###### 

*EGFR* Mutation Frequency Comparisons Among Subgroups
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DISCUSSION {#s11}
==========

In this study, which is the largest to our knowledge to prospectively evaluate the frequency of *EGFR* mutations in CLIA-certified laboratories in Latino patients with NSCLC from the United States and Latin America, there was no difference in the frequency of *EGFR* mutations between Latinos and non-Latinos. Although we observed a significant difference in the frequency of *EGFR* mutations among the different racial and ethnic subgroups studied, this difference was not significant when non-Latino Asians and blacks were removed from the analysis. This is consistent with previous reports that have observed a significantly higher frequency of *EGFR* mutations in Asians. Furthermore, the samples analyzed were part of a multiethnic and international cohort of patients with NSCLC, which allowed us to make comparisons among racial and ethnic groups rather than relying on historical controls. Finally, an additional strength of this study was that molecular testing was performed in two CLIA-certified central laboratories, avoiding quality control issues and potential variability in *EGFR* mutation frequency resulting from differences in testing methods used in different countries.

However, this study has limitations that underscore important aspects of cancer molecular characterization studies in Latinos and other under-represented minority populations in the United States. First, enrollment of Latino patients in the United States was low (30 \[7%\] of 420), despite the fact that one of the protocols in this study (NCT01255150) was specifically geared toward enrollment of such patients. Furthermore, despite the establishment of collaborations with several large cancer centers in Latin America to address the challenges described in this article, the number of Latinos overall was low. This problem highlights the significant difficulties of research collaborations with developing countries in which resource constraints, logistic, and legal challenges may significantly affect enrollment. This is in line with previous experience in other molecular characterization studies and clinical trials. Furthermore, it partially explains the paucity of tumor-specific molecular characterization data in Latinos and other minority populations in the United States. In this particular case, although the first reports of the frequency of *EGFR* mutations in NSCLC in the United States date back to 2004,^[@B17]^ the initial report for Latinos in the United States came almost a decade later,^[@B11]^ and the total number of reports and patients tested by race or ethnicity differs significantly between majority and minority populations. Of utmost importance is that in the event the cancer molecular profile of a particular minority population would differ significantly from the majority, such a disparity in molecular data availability could lead to the worsening of the already existing outcome disparities among patients of different races or ethnicities in the United States.

Another potential limitation of our study is that we did not account for the significant racial and genetic differences that exist within the Latino population. This population is significantly heterogeneous and in our study was defined based on either a geographic definition (ie, Latin America) or self-identification^[@B18]^ and included individuals of different races (eg, Latino whites, Latino American Indians, and Latino blacks). In this study, we did not collect information on race in the Latino population, nor did we perform genetic ancestry analyses or germline ancestry informative markers that could characterize the genetic origin within admixed populations.^[@B19]^ It is possible that we may have primarily sampled a subset of Latino patients with NSCLC, such as the Latino white population. Because this population is similar, in terms of genetic ancestry, to the non-Latino white population in the United States, this may have obscured a potential difference in *EGFR* mutation frequency between the two groups. However, Latinos with American Indian ancestry are of special interest, given that they represent the majority population in Mexico, Central America, and parts of South America (eg, Peru), and Latinos from such geographic areas comprise the largest subgroup of Latinos in the United States. Thus, we may not have captured a significant portion of the population of interest (ie, Latino American Indians), resulting in the negative results presented here. Conversely, the observation of a high *EGFR* mutation frequency in patients from Peru, which is known to have a large percentage of Latinos with high American Indian ancestry, could be an indication that there may in fact be a higher *EGFR* mutation frequency in a subset of Latinos defined by high American Indian ancestry. Alternatively, this could be related to sampling of a Peruvian population of Chinese and Japanese descent, which is also among the largest in Latin America.^[@B20]^ This underscores the need to account for race and genetic ancestry analysis in future studies.

Finally, it is important to note that the *EGFR* mutation frequency in the non-Latino white population of our cohort was considerably higher than what has been described in historical controls. This is likely the result of an unintended patient selection bias related to the fact that the populations of patients seeking care at large research institutions in the United States (eg, NCI and OHSU) tend to have clinical characteristics that have been associated with a higher frequency of *EGFR* mutations (eg, never smokers and adenocarcinoma histology).^[@B21]^ This is of utmost importance, because our conclusions are based on a comparator arm for which *EGFR* mutation frequency may have been overestimated as a result of selection bias. Thus, this comparison may not be appropriate, and our conclusions may not be accurate. This may explain the contrasting conclusions reached by this and other studies, particularly that conducted by Arrieta et al,^[@B10]^ in which the *EGFR* mutation frequency of a large (N = 5,738) retrospective cohort of NSCLC samples from different countries in Latin America was analyzed. In that study, a frequency of 26% was found, which was compared with a historical control of 15% in non-Latino patients from the United States; thus, the authors concluded that the *EGFR* mutation frequency in Latinos was higher. In contrast, Zhang et al^[@B11]^ evaluated *EGFR* mutations in lung adenocarcinomas from US Latino patients and found an *EGFR* mutation frequency of 15% (six of 40), which was similar to that observed in non-Latino white patients (eight \[18.6%\] of 43).

Our study provides what is to our knowledge the first prospective assessment of *EGFR* mutation frequency in CLIA-certified laboratories among Latinos from the United States and Latin America and allows comparison with frequencies among US non-Latino patients of different races. Although we did not observe a difference in the frequency of *EGFR* mutations between Latinos and non-Latinos, our results should be interpreted with caution, given the significant limitations of the study. Furthermore, our observations are inconclusive, and more research is needed to better understand the molecular characteristics of NSCLC in Latinos, with a particular focus on the role of race and genetic admixture and its molecular implications and the determination of its impact on the treatment and outcome of all patients with NSCLC regardless of race or ethnicity.
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